Table 3.
Ongoing asthma therapies concomitant to omalizumab during the observational period by gender
| Treatment regimen | Females (N = 54) n (%) |
Males (N = 34) n (%) |
p-value* |
|---|---|---|---|
| No ongoing therapies | 1 (1.9) | 0 (0.0) | 0.281 |
| ICS | 43 (79.6) | 31 (91.2) | |
| ICS only | 3 (5.6) | 3 (8.8) | |
| ICS/LABA only | 33 (61.1) | 21 (61.8) | |
| ICS + ICS/LABA | 7 (13.0) | 7 (20.6) | |
| OCS | 10 (18.5) | 3 (8.8) | |
| ICS/LABA + OCS | 5 (9.3) | 1 (2.9) | |
| ICS + ICS/LABA + OCS | 3 (5.6) | 0 (0.0) | |
| ICS + OCS | 2 (3.7) | 2 (5.9) |
Only therapies that were ongoing at baseline and at 6 and 12 months were considered.ICS: inhaled corticosteroids; ICS/LABA: fixed combination of ICS and LABA; LABA: long acting beta2-agonists; OCS: oral corticosteroids
*P-value of Fisher exact test treatment regimen (no ongoing therapies, ICS, OCS) vs gender (females, males) is showed